Insmed, Inc. $INSM Shares Bought by Andra AP fonden

Key Points

• Andra AP fonden increased its Insmed position by 55.9% in the second quarter, purchasing 43,600 additional shares for a total stake valued at approximately $13.0 million. Other institutional investors, including C WorldWide Group, also raised their holdings.
• Insmed reported better-than-expected quarterly results, with revenue rising 296.1% year over year to $425.5 million and adjusted EPS of -$0.06 versus the -$0.67 consensus estimate. Analysts maintain a consensus “Buy” rating with an average price target of $204.91.
• Insiders sold nearly $38.5 million of stock during the latest quarter, while the company remains loss-making. Investors are focused on potential growth from ARIKAYCE’s FDA priority-review label expansion, which has a target decision date of January 28, 2027.

Andra AP fonden raised its position in Insmed, Inc. (NASDAQ:INSM - Free Report) by 55.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 121,570 shares of the biopharmaceutical company's stock after buying an additional 43,600 shares during the quarter. Andra AP fonden owned approximately 0.06% of Insmed worth $12,962,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. WINTON GROUP Ltd purchased a new position in shares of Insmed during the second quarter worth about $400,000. C WorldWide Group Holding A S increased its stake in Insmed by 62.1% in the 2nd quarter. C WorldWide Group Holding A S now owns 261,110 shares of the biopharmaceutical company's stock valued at $27,840,000 after buying an additional 100,000 shares during the period. NewEdge Advisors LLC increased its stake in Insmed by 22.3% in the 2nd quarter. NewEdge Advisors LLC now owns 7,354 shares of the biopharmaceutical company's stock valued at $784,000 after buying an additional 1,339 shares during the period. IFP Advisors Inc lifted its stake in shares of Insmed by 28.5% in the 2nd quarter. IFP Advisors Inc now owns 2,945 shares of the biopharmaceutical company's stock worth $314,000 after acquiring an additional 654 shares during the period. Finally, Arizona State Retirement System lifted its stake in shares of Insmed by 4.1% in the 2nd quarter. Arizona State Retirement System now owns 60,340 shares of the biopharmaceutical company's stock worth $6,433,000 after acquiring an additional 2,389 shares during the period.

Insider Transactions at Insmed

In related news, Director David Brennan sold 25,000 shares of the firm's stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the sale, the director directly owned 39,238 shares in the company, valued at approximately $4,865,512. This trade represents a 38.92% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO William Lewis sold 10,699 shares of the company's stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $117.40, for a total transaction of $1,256,062.60. Following the completion of the transaction, the chief executive officer directly owned 259,058 shares of the company's stock, valued at approximately $30,413,409.20. The trade was a 3.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 296,947 shares of company stock valued at $38,531,713 over the last quarter. Company insiders own 2.10% of the company's stock.

Insmed Stock Down 0.1%

INSM stock opened at $120.82 on Wednesday. Insmed, Inc. has a one year low of $90.39 and a one year high of $212.75. The company has a 50 day moving average price of $118.95 and a two-hundred day moving average price of $122.62. The company has a debt-to-equity ratio of 0.74, a quick ratio of 3.40 and a current ratio of 3.72. The stock has a market capitalization of $26.38 billion, a P/E ratio of -29.40 and a beta of 0.82.

Insmed (NASDAQ:INSM - Get Free Report) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.67) by $0.61. Insmed had a negative return on equity of 123.94% and a negative net margin of 76.94%.The firm had revenue of $425.49 million for the quarter, compared to analysts' expectations of $395.50 million. During the same quarter last year, the firm earned ($1.70) earnings per share. The firm's revenue for the quarter was up 296.1% compared to the same quarter last year. As a group, sell-side analysts expect that Insmed, Inc. will post -1.84 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Evercore reiterated an "outperform" rating and set a $170.00 price target on shares of Insmed in a research note on Friday, August 7th. Mizuho set a $192.00 price target on Insmed in a research note on Tuesday, June 16th. HC Wainwright restated a "buy" rating on shares of Insmed in a report on Monday, August 10th. JPMorgan Chase & Co. lowered their price target on shares of Insmed from $179.00 to $175.00 and set an "overweight" rating on the stock in a research report on Monday, August 10th. Finally, Wells Fargo & Company raised their price objective on shares of Insmed from $161.00 to $169.00 and gave the stock an "overweight" rating in a research note on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $204.91.

Key Stories Impacting Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: FDA priority review for ARIKAYCE: The FDA accepted Insmed’s filing seeking to expand ARIKAYCE’s use in combination therapy for MAC lung disease, potentially allowing treatment earlier in the disease course rather than primarily in patients with refractory disease. The agency set a PDUFA target action date of January 28, 2027. The filing is supported by positive Phase 3b ENCORE results and would also satisfy an FDA post-marketing requirement. FDA Grants Priority Review to Insmed's ARIKAYCE sNDA
• Positive Sentiment: Potential commercial expansion: Approval could materially enlarge ARIKAYCE’s addressable patient population and strengthen Insmed’s long-term revenue outlook. The priority designation also accelerates the regulatory review timeline, although it does not guarantee approval. FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce
• Positive Sentiment: Broader pipeline optimism: A bullish analyst view highlights strong Brinsupri launch potential, reported first-half 2026 revenue of $517 million, limited competition and possible peak sales exceeding $7 billion. Positive Phase 2b TPIP data could support additional Phase 3 programs and significant future sales if successful. Insmed: Expensive Stock, But Discount To Recent Highs Makes Bull Case
• Negative Sentiment: Valuation and execution risk: Insmed remains a loss-making biotechnology company, and the stock’s valuation depends heavily on successful launches, clinical development and future regulatory approvals. Investors must also wait for the January 2027 ARIKAYCE decision.

About Insmed

Insmed Incorporated NASDAQ: INSM is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases. The company's work centers on areas of significant unmet medical need, including pulmonary and infectious diseases, as well as other specialty conditions.

Insmed's primary commercial product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibacterial therapy approved in the United States for adults with refractory Mycobacterium avium complex lung disease as part of a combination antibacterial regimen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.